Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBeatriz Chiclana-RodríguezJRJuan Luis RegueraECEusebio Martín Chacón

Discussion

Loading...

Member takes

Overview

Retrospective study finds similar toxicity and efficacy for melphalan doses in stem cell transplantation for multiple myeloma.

Key Points

  • Toxicity parameters showed no significant differences between melphalan doses in autologous stem cell transplantation patients.
  • Overall survival rates were comparable, with 85.1% for 140 mg/m² and 89.7% for 200 mg/m² melphalan.
  • Doses of melphalan were evaluated in 282 patients undergoing hematopoietic stem cell transplantation between 2018 and 2024.
  • Findings suggest lower doses of melphalan may be effective for frail patients without compromising outcomes.

Cite This Study

Chiclana-Rodríguez et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da92https://doi.org/10.1182/blood-2025-4061
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age2025
  2. 2Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data2025 · 1 citations
  3. 3Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide2025
  4. 4Comparative outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis2025
  5. 5Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study2025